GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Telo Genomics Corp (OTCPK:TDSGF) » Definitions » Cyclically Adjusted PB Ratio

Telo Genomics (Telo Genomics) Cyclically Adjusted PB Ratio : 0.72 (As of Apr. 28, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Telo Genomics Cyclically Adjusted PB Ratio?

As of today (2024-04-28), Telo Genomics's current share price is $0.1232. Telo Genomics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $0.17. Telo Genomics's Cyclically Adjusted PB Ratio for today is 0.72.

The historical rank and industry rank for Telo Genomics's Cyclically Adjusted PB Ratio or its related term are showing as below:

TDSGF' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.89
Current: 0.7

During the past years, Telo Genomics's highest Cyclically Adjusted PB Ratio was 0.89. The lowest was 0.00. And the median was 0.00.

TDSGF's Cyclically Adjusted PB Ratio is ranked better than
77.1% of 131 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.98 vs TDSGF: 0.70

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Telo Genomics's adjusted book value per share data for the three months ended in Dec. 2023 was $0.013. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.17 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Telo Genomics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Telo Genomics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telo Genomics Cyclically Adjusted PB Ratio Chart

Telo Genomics Annual Data
Trend Dec13 Dec14 Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 1.04 1.07

Telo Genomics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.16 0.93 1.07 0.88 0.83

Competitive Comparison of Telo Genomics's Cyclically Adjusted PB Ratio

For the Diagnostics & Research subindustry, Telo Genomics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telo Genomics's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Telo Genomics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Telo Genomics's Cyclically Adjusted PB Ratio falls into.



Telo Genomics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Telo Genomics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.1232/0.17
=0.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telo Genomics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Telo Genomics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.013/125.4675*125.4675
=0.013

Current CPI (Dec. 2023) = 125.4675.

Telo Genomics Quarterly Data

Book Value per Share CPI Adj_Book
201403 0.497 98.604 0.632
201406 0.543 99.473 0.685
201409 0.522 99.394 0.659
201412 0.480 98.367 0.612
201503 0.435 99.789 0.547
201506 0.436 100.500 0.544
201509 0.468 100.421 0.585
201512 0.409 99.947 0.513
201603 0.392 101.054 0.487
201606 0.392 102.002 0.482
201609 0.323 101.765 0.398
201612 0.453 101.449 0.560
201703 0.328 102.634 0.401
201706 0.157 103.029 0.191
201709 0.090 103.345 0.109
201712 0.104 103.345 0.126
201803 0.056 105.004 0.067
201806 -0.019 105.557 -0.023
201809 -0.033 105.636 -0.039
201812 -0.041 105.399 -0.049
201903 -0.047 106.979 -0.055
201906 -0.059 107.690 -0.069
201909 -0.067 107.611 -0.078
201912 0.022 107.769 0.026
202003 0.017 107.927 0.020
202006 0.014 108.401 0.016
202009 0.013 108.164 0.015
202012 0.026 108.559 0.030
202103 0.030 110.298 0.034
202106 0.054 111.720 0.061
202109 0.051 112.905 0.057
202112 0.048 113.774 0.053
202203 0.043 117.646 0.046
202206 0.034 120.806 0.035
202209 0.026 120.648 0.027
202212 0.018 120.964 0.019
202303 0.010 122.702 0.010
202306 0.028 124.203 0.028
202309 0.021 125.230 0.021
202312 0.013 125.468 0.013

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Telo Genomics  (OTCPK:TDSGF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Telo Genomics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Telo Genomics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Telo Genomics (Telo Genomics) Business Description

Traded in Other Exchanges
Address
101 College Street, Suite 200, MaRS Centre, South Tower, Toronto, ON, CAN, M5G 1L7
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in the development and commercialization of diagnostic and prognostic products. The company is developing diagnostic and prognostic products for cancer and neurological disorders.